{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:19:27Z","timestamp":1790518767794,"version":"4.1.0"},"reference-count":66,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,9,20]]},"abstract":"<jats:p>Maribavir was approved by the U.S. Food and Drug Administration in November 2021 for the treatment of adult and pediatric patients with post-transplant cytomegalovirus (CMV) infection\/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet.<\/jats:p>","DOI":"10.1128\/aac.02405-21","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T09:26:22Z","timestamp":1659432382000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":52,"title":["New Perspectives on Antimicrobial Agents: Maribavir"],"prefix":"10.1128","volume":"66","author":[{"given":"Virginie","family":"Halpern-Cohen","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Ruth and Raymond Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-6170","authenticated-orcid":true,"given":"Emily A.","family":"Blumberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Ruth and Raymond Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz454"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2015(07)09"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679639"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.5935\/0101-2800.20170074"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12686"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112666"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13521"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12852"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090424"},{"key":"e_1_3_2_12_2","first-page":"2502","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome","volume":"90","author":"Salzberger B","year":"1997","unstructured":"Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. 1997. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood, the J the American Society of Hematology 90:2502\u20132508.","journal-title":"Blood, the J the American Society of Hematology"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2015.266"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13058"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq368"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2007.00761.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/338143"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2010.07.001"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix259"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001418"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00561-13"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.06.009"},{"key":"e_1_3_2_23_2","volume-title":"US FDA","author":"Administration US FDA","year":"2021","unstructured":"Administration US FDA. 2021. FDA approves first treatment for common type of post-transplant infection that is resistant to other drugs. US FDA, Silver Spring, MD. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-common-type-post-transplant-infection-resistant-other-drugs. Accessed March 15, 2022."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2365-2372.2002"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2186-2192.2003"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.3918-3927.2004"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000275"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.2.905-914.2003"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2006.07.010"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab988"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.14.7720-7727.2003"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/518514"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.615"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00577-06"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0166-3542(02)00094-3"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1468-1471.2003"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.07.013"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1334-1342.2003"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy706"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714656"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.2969-2976.2002"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1130-1135.2006"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.12.335"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.554"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2011.10.011"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2373-2380.2002"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02768.x"},{"key":"e_1_3_2_48_2","article-title":"Lack of drug-drug interaction between maribavir and voriconazole [abstract]","volume":"20","author":"Song I","year":"2020","unstructured":"Song I, Ilic K, Wu J. 2020. Lack of drug-drug interaction between maribavir and voriconazole [abstract]. Am J Transplant 20 (Suppl 3). Available from https:\/\/atcmeetingabstracts.com\/abstract\/lack-of-drug-drug-interaction-between-maribavir-and-voriconazole\/.","journal-title":"Am J Transplant"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006296765"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12814"},{"key":"e_1_3_2_51_2","unstructured":"Takeda. 2021. Liventicity: highlights of prescribing information. Takeda Pharmaceuticals Intl AG Opfikon Switzerland. https:\/\/content.takeda.com\/?contenttype=pi&product=liv&language=eng&country=usa&documentnumber=1. Accessed March 11 2022."},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-31047-3_11"},{"key":"e_1_3_2_53_2","unstructured":"Takeda (Antimicrobial Drugs Advisory Committee). 2021. Maribavir: sponsor briefing document. Takeda Pharmaceuticals Intl AG Opfikon Switzerland. Available from https:\/\/www.fda.gov\/media\/152715\/download. Accessed March 11 2022."},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.574"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01787-07"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.05.013"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa462"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104616"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.13.7124-7130.2004"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01177-08"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2011.01.006"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2011.02.001"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-121558"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70024-X"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04231.x"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.01.082"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2010.00550.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02405-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02405-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T09:12:12Z","timestamp":1663665132000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.02405-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":66,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,20]]}},"alternative-id":["10.1128\/aac.02405-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.02405-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"2022-08-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02405-21"}}